Stocks and Investing Stocks and Investing
Fri, February 16, 2024
Thu, February 15, 2024

Keay Nakae Maintained (SONN) at Strong Buy with Decreased Target to $240 on, Feb 15th, 2024


Published on 2024-10-28 09:00:35 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy with Decreased Target from $600 to $240 on, Feb 15th, 2024.

Keay has made no other calls on SONN in the last 4 months.



There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Keay's Rating of Hold.



This is the rating of the analyst that currently disagrees with Keay


  • Ahu Demir of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $56 on, Monday, November 27th, 2023
Contributing Sources